Fluconazole

Diflucan

Antifungal • Azole antifungal

Premium

QT RiskHepatotoxic

Half-life

30 hours

Protein Binding

11-12%

Metabolized By

CYP2C9, CYP3A4

External

Drugs.com

Clinical alerts

QT prolongation

Avoid combining with other QT-prolonging agents; check electrolytes

Hepatotoxic

Monitor liver function

Mechanism of action

Inhibits fungal CYP450-dependent lanosterol demethylase

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Leukemia, Myeloid, Acute
·Leukemia, Lymphocytic, Acute
·Multiple Myeloma
·Myelodysplastic Syndromes
·Bacterial Vaginosis

Monitoring

Therapeutic range: 11–25 mg/L; AUC/MIC > 25-50

Interactions

3 curated · 3 major or contraindicated · select a row for management

Interacting drug	Severity	Effect
rifampicin	major	Reduced antifungal efficacy; risk of treatment failure for fungal infections.
tacrolimus	major	Tacrolimus toxicity: nephrotoxicity, neurotoxicity, hyperkalemia
warfarin	major	INR may increase 2-4 fold, causing significant bleeding risk.

Common adverse effects

Nausea
Headache
Rash
Elevated LFTs

Food, alcohol & herbal

Alcohol · moderate

Additive hepatotoxicity risk

Pharmacokinetics

Published parameters · PMID:10344570

Half-life: 30 hours
Protein binding: 11-12%
Inhibits: CYP2C9, CYP2C19, CYP3A4
Clearance: 1.5 L/h; adult patients
Volume of distribution: 50 L
Bioavailability: 90%
Renally eliminated: 80%; Dose review in renal impairment
Model: 1-compartment

Pregnancy & lactation

Not recorded for Fluconazole. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database, curated interaction pairs, published PK literature.

Not a substitute for clinical judgement